Before we get to Dr. Joseph Mercola's article below, I thought I would offer my two conspiratorial cents on what's driving Molnupiravir to be released instead of Ivermectin against Covid-19.
The article below does a fine job at applying the science to the Ivermectin vs Molnupiravir debate.
STORY AT-A-GLANCE. One paper compared Merck's data on molnupiravir against peer-reviewed data on ivermectin and found ivermectin has a low side effect profile, costs less than molnupiravir and is more effective against SARS-CoV-2.
Campbell compares the efficacy, safety and cost using available data for ivermectin published in peer reviewed studies and the first interim data for molnupiravir published by Merck.
Ivermectin is the "Most studied, 'repurposed' medication globally, in randomized clinical trials, retrospective studies and meta-analysis." Ivermectin is an FDA-approved, broad spectrum antiparasitic17.
By comparison, Merck claims molnupiravir is a broad-spectrum antiviral that is active against the Gamma, Delta and Mu SARS-CoV-2 variants.
The amount of time the maximum drug dose is found in the serum is one to 1.75 hours for molnupiravir and four to six hours for ivermectin.
https://noqreport.com/2021/10/25/ivermectin-vs-mercks-new-antiviral-molnupiravir/
No comments:
Post a Comment